PRESS RELEASE

February 7, 2005

Company Press Release

SOURCE: : Intarcia Therapeutics, Inc.

Intarcia Therapeutics Files Registration Statement For Initial Public Offering

Emeryville, Ca, – February 7, 2005 –- Intarcia Therapeutics Inc., a privately held biopharmaceutical company, today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

The lead underwriter of the offering will be Credit Suisse First Boston, LLC, acting as sole book-running manager, with Pacific Growth Equities, LLC and Lazard Fréres & Co LLC as co-managers.
A written preliminary prospectus related to the offering may be obtained when available from the prospectus department of Credit Suisse First Boston LLC (One Madison Avenue, New York, New York 10010; 212-325-2580).

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state.

About Intarcia
Intarcia Therapeutics Inc, a privately held pharmaceutical company, is developing therapies for the treatment of cancer, immunological, and infectious diseases. The company specializes in redirecting the development of drugs to new indications which meet significant unmet medical needs. The company has agreements with ALZA Corporation, Boehringer Ingelheim, Chiron, Pfizer and Schering AG. Based in Emeryville, California, the Company is privately held and backed by premier investors, including Alta Partners, Brentwood Associates, Delphi Ventures, InterWest Partners, New Enterprise Associates, and Venrock Associates. More information about the company is available at www.intarcia.com.

# # #

Contact: James Ahlers
Chief Financial Officer
Intarcia Therapeutics
510-652-2600 ext 235

| Back |